Institutional members access full text with Ovid®

Share this article on:

The Neuropsychiatric Inventory Scores Change Across the Mini Mental State Examination Ranges in Patients With Alzheimer's Disease: A Multicenter Study in Turkey

Yener, Görsev G. MD, PhDand Turkuaz Alzheimer Working (TAÇ) Group

Cognitive and Behavioral Neurology: December 2009 - Volume 22 - Issue 4 - p 264-269
doi: 10.1097/WNN.0b013e3181c14737
Original Studies

Objective To investigate neuropsychiatric manifestations in patients at various stages of Alzheimer's disease (AD).

Background Several earlier studies reported high prevalence of neuropsychiatric symptoms in patients with AD; to date, no such study has been conducted in Turkey.

Method We evaluated 217 patients with AD from 18 referral centers across Turkey using a web-based dementia data registry. The Mini Mental State Examination and the Neuropsychiatric Inventory (NPI) were used to evaluate the global cognitive function, and assessment of neuropsychiatric symptoms, respectively. We classified the patients into mild, moderate, and severe stages on the basis of their Mini Mental State Examination scores. We assessed group differences and correlations between the degree of AD severity and NPI values.

Results The highest NPI scores were seen in patients with severe AD. The mean composite scores for apathy, anxiety, and depression were the highest. The prevalence of any behavioral symptom was 86%. There was no difference in the behavioral domain between the groups or between the referral centers. Moderate correlation was found between the severity of AD and the total NPI score. The caregivers' NPI distress scores varied among referral centers.

Conclusions The prevalence of behavioral disturbance in AD is high and similar to earlier studies, yet regional differences are seen in caregivers' reactions to behavioral symptoms.

Department of Neurology and Neurosciences, Brain Dynamics Multidisciplinary Research and Application Center, Dokuz Eylul University, Izmir Turkey

Financial Support: the TAÇ web-based dementia registry was supported by the Sanovel Drug Company, Turkey.

Reprints: Görsev G. Yener, MD, PhD, Departments of Neurology and Neurosciences, Dokuz Eylul University, Izmir, 35340, Turkey (e-mail:

Received for publication December 15, 2008

accepted September 13, 2009

Disclosure: none declared.

© 2009 Lippincott Williams & Wilkins, Inc.